497 related articles for article (PubMed ID: 24750101)
1. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.
Judge HM; Jennings LK; Moliterno DJ; Hord E; Ecob R; Tricoci P; Rorick T; Kotha J; Storey RF
Platelets; 2015; 26(3):236-42. PubMed ID: 24750101
[TBL] [Abstract][Full Text] [Related]
2. Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions.
Hosokawa K; Ohnishi T; Miura N; Sameshima H; Koide T; Tanaka KA; Maruyama I
Thromb Res; 2014 Jan; 133(1):66-72. PubMed ID: 24268424
[TBL] [Abstract][Full Text] [Related]
3. In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist.
Hawes BE; Zhai Y; Hesk D; Wirth M; Wei H; Chintala M; Seiffert D
Eur J Pharmacol; 2015 Sep; 762():221-8. PubMed ID: 26022529
[TBL] [Abstract][Full Text] [Related]
4. Protease-Activated Receptor 4 Variant p.Tyr157Cys Reduces Platelet Functional Responses and Alters Receptor Trafficking.
Norman JE; Cunningham MR; Jones ML; Walker ME; Westbury SK; Sessions RB; Mundell SJ; Mumford AD
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):952-60. PubMed ID: 26966273
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood.
French SL; Arthur JF; Lee H; Nesbitt WS; Andrews RK; Gardiner EE; Hamilton JR
J Thromb Haemost; 2016 Aug; 14(8):1642-54. PubMed ID: 26878340
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation.
Wu CC; Teng CM
Eur J Pharmacol; 2006 Sep; 546(1-3):142-7. PubMed ID: 16890935
[TBL] [Abstract][Full Text] [Related]
7. Contributions of Protease-Activated Receptors PAR1 and PAR4 to Thrombin-Induced GPIIbIIIa Activation in Human Platelets.
Duvernay MT; Temple KJ; Maeng JG; Blobaum AL; Stauffer SR; Lindsley CW; Hamm HE
Mol Pharmacol; 2017 Jan; 91(1):39-47. PubMed ID: 27784794
[TBL] [Abstract][Full Text] [Related]
8. Platelet activation via PAR4 is involved in the initiation of thrombin generation and in clot elasticity development.
Vretenbrant K; Ramström S; Bjerke M; Lindahl TL
Thromb Haemost; 2007 Mar; 97(3):417-24. PubMed ID: 17334509
[TBL] [Abstract][Full Text] [Related]
9. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy.
Storey RF; Kotha J; Smyth SS; Moliterno DJ; Rorick TL; Moccetti T; Valgimigli M; Dery JP; Cornel JH; Thomas GS; Huber K; Harrington RA; Hord E; Judge HM; Chen E; Strony J; Mahaffey KW; Tricoci P; Becker RC; Jennings LK
Thromb Haemost; 2014 May; 111(5):883-91. PubMed ID: 24402559
[TBL] [Abstract][Full Text] [Related]
10. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
Bilodeau ML; Hamm HE
J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
[TBL] [Abstract][Full Text] [Related]
11. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets.
Covic L; Gresser AL; Kuliopulos A
Biochemistry; 2000 May; 39(18):5458-67. PubMed ID: 10820018
[TBL] [Abstract][Full Text] [Related]
12. The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y
Whitley MJ; Henke DM; Ghazi A; Nieman M; Stoller M; Simon LM; Chen E; Vesci J; Holinstat M; McKenzie SE; Shaw CA; Edelstein LC; Bray PF
J Thromb Haemost; 2018 Dec; 16(12):2501-2514. PubMed ID: 30347494
[TBL] [Abstract][Full Text] [Related]
13. PAR4, but not PAR1, signals human platelet aggregation via Ca2+ mobilization and synergistic P2Y12 receptor activation.
Holinstat M; Voss B; Bilodeau ML; McLaughlin JN; Cleator J; Hamm HE
J Biol Chem; 2006 Sep; 281(36):26665-74. PubMed ID: 16837456
[TBL] [Abstract][Full Text] [Related]
14. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin.
Kahn ML; Nakanishi-Matsui M; Shapiro MJ; Ishihara H; Coughlin SR
J Clin Invest; 1999 Mar; 103(6):879-87. PubMed ID: 10079109
[TBL] [Abstract][Full Text] [Related]
15. Platelet protease-activated receptor (PAR)4, but not PAR1, associated with neutral sphingomyelinase responsible for thrombin-stimulated ceramide-NF-κB signaling in human platelets.
Chen WF; Lee JJ; Chang CC; Lin KH; Wang SH; Sheu JR
Haematologica; 2013 May; 98(5):793-801. PubMed ID: 23065519
[TBL] [Abstract][Full Text] [Related]
16. Platelet thrombin receptor antagonism with vorapaxar: pharmacology and clinical trial development.
Franchi F; Rollini F; Park Y; Angiolillo DJ
Future Cardiol; 2015 Sep; 11(5):547-64. PubMed ID: 26406386
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of PAR4 signaling mediates ethanol-induced attenuation of platelet function in vitro.
Kasuda S; Sakurai Y; Shima M; Morimura Y; Kudo R; Takeda T; Ishitani A; Yoshioka A; Hatake K
Alcohol Clin Exp Res; 2006 Sep; 30(9):1608-14. PubMed ID: 16930224
[TBL] [Abstract][Full Text] [Related]
18. The ATP-gated P2X1 receptor plays a pivotal role in activation of aspirin-treated platelets by thrombin and epinephrine.
Grenegård M; Vretenbrant-Oberg K; Nylander M; Désilets S; Lindström EG; Larsson A; Ramström I; Ramström S; Lindahl TL
J Biol Chem; 2008 Jul; 283(27):18493-504. PubMed ID: 18480058
[TBL] [Abstract][Full Text] [Related]
19. Thrombin induces platelet activation in the absence of functional protease activated receptors 1 and 4 and glycoprotein Ib-IX-V.
Lova P; Canobbio I; Guidetti GF; Balduini C; Torti M
Cell Signal; 2010 Nov; 22(11):1681-7. PubMed ID: 20600849
[TBL] [Abstract][Full Text] [Related]
20. PAR4-Mediated PI3K/Akt and RhoA/ROCK Signaling Pathways Are Essential for Thrombin-Induced Morphological Changes in MEG-01 Cells.
Heo Y; Jeon H; Namkung W
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
